Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Stunning Data of RMC6236 Combined with PD1 Immunotherapy in CT26-KRAS ...
RMC6236 | 2765081-21-6
2764998-32-3 | RMC6236中间体1 | RMC6236 Intermediate 1 - CATO佳途
RMC-6236 - Oral RAS-Selective Tri-Complex Inhibitor for Cancer - Biofargo
RMC-6236
AACR24 | RMC-6236结构正式公开，那些年它的follower们医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
RMC-6236: a pan-RAS inhibitor from Revolution Medicines | Drug Hunter ...
RMC-6236 / Revolution Medicines
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC ...
剑指“癌症之王”，多款KRAS抑制剂展现抗癌活性
AACR24|RMC-6236结构正式公开，那些年它的follower们_财富号_东方财富网
医药魔方
8 RAS(ON) Multi-Selective Inhibitor RMC-6236 © 2023 RevolutionMedicines ...
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable ...
Revolution：RMC-6236即将启动一线胰腺癌的三期临床
Study of RMC-6236 and Pembrolizumab with or without Chemotherapy for ...
【JMC】RMC-6236 分子发现与设计 - 知乎
RAS(ON) Multi-Selective Inhibition Enhances Antitumor Immunity in ...
RMC-6236 - Chemietek
Daraxonrasib (RMC-6236): Clinical Development of a RAS(ON) Inhibitor ...
Slide 9
First Patient Dosed in Study of RMC-6236 in KRAS-Driven Advanced Solid ...
RMC-6236 | CAS:2765081-21-6 | Ark Pharma Scientific Limited
RMC-6236 for Non-Small Cell Lung Cancer Clinical Trial 2023 | Power
A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced ...
Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON ...
Phase 1 Data Support Further Investigation of RMC-6236 in KRAS-Mutant ...
LOGO
疾病控制率近90%，RMC-6236能否实现对KRAS的“通杀”？
Comprehensive Analysis of Daraxonrasib (RMC-6236) Resistance Across ...
Slide 27
RMC-6236 Shows Safety, Efficacy in KRAS G12X Tumors
Abstract PR010: Preliminary safety and pharmacokinetic profiles of RMC ...
Avanços Contra o Câncer de Tumores Sólidos: Estudo do RMC-6236 ...
New Pancreatic Ductal Adenocarcinoma Clinical Trial: RMC 6236 for ...
RMC-6236 Shows Safety, Efficacy in KRAS G12X Tumors | Targeted Oncology ...
Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy ...
RAS抑制剂研发热潮！RMC-7977和RMC-6236抑制剂有望为RAS突变型肿瘤的治疗带来新希望
RMC-6272 causes apoptosis specifically in ER+ breast cancer cells A A ...
Daraxonrasib (RMC-6236) | Certificate of Analysis
RMC-6236 appeared safe and tolerable, alongside a reduction in tumor ...
(3)
RMC-6236 在胰腺导管腺癌患者中的数据公布
Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA ...
Slide 10
RMC-6236单药治疗胰腺导管腺癌和非小细胞肺癌的1期RMC-6236-001 研究的最新临床数据公布
PDAC with ctDNA Study on RMC-6236 Shows Promising Results at ASCO GI ...
RMC-6236 2765081-21-6 - ChemicalBook
RMC-6236 Shows Activity With Favorable Toxicity Profile in Previously ...
RMC-6236 | Excenen PharmaTech
RCSB PDB - 9AX6: Tricomplex of RMC-6236, KRAS G12D, and CypA
Combination of BGB‐283 and selumetinib exhibited enhanced antitumor ...
RMC6236中间体 - ChemicalBook
RAS(ON)多选择性抑制剂RMC-6236 胰腺癌I期结果积极医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA ...
活性分子专栏｜Daraxonrasib（RMC-6236）的分子发现思考与临床前景 - 知乎
数据惊艳丨KRAS泛靶点靶向药RMC-6236，启动多项3期临床试验 - 知乎
Effect of rhMG53 on the volume and weight of tumors in SW620 tumor ...
Daraxonrasib (RMC-6236) RAS-IN-2 CAS#2765081-21-6体内体外试验方法，多靶点KRAS、NRAS ...
RMC-6236 for the Treatment of Pancreatic Ductal Adenocarcinoma - YouTube
Knockdown of PDCD1/PDCD1LG1 promotes in vivo tumor growth and enhances ...
RMC-6236 (Daraxonrasib): 广谱RAS(ON)抑制剂的突破与临床前景
,%20Colorectal%20Carcinoma%20(CRC),%20Pancreatic%20Adenocarcinoma%20(Ductal%20Adenocarcinoma):%0A%0ARMC-6236%20for%20Non-Small%20Cell%20Lung%20Cancer.png?md=1)
